Crucial Innovations Pivots to Cannabis, Faces Uphill Battle

TL;DR

**Crucial Innovations is a speculative bet on a cannabis startup with no current trading, limited cash, and a highly competitive market; avoid until they prove commercial viability.**

AI Summary

Crucial Innovations Corp. (CINV), a Nevada corporation formed in 2018, pivoted its business in 2023 from English language tutoring to becoming a supplier and distributor of medical cannabis in Europe. The company has not achieved significant operations or commercial sales in its new venture. CINV's shares previously traded on the OTC Markets expert trading platform under 'CINV' but are currently not traded on any exchange. The company intends to re-apply to OTC Markets to resume trading after filing this 10-K. As of December 31, 2024, there were 381,320,798 shares of common stock outstanding, increasing to 418,694,150 shares by August 14, 2025. The European medical cannabis market is highly competitive with significant barriers to entry due to licensing requirements, and CINV faces competition from established cannabis producers and broader consumer product manufacturers. The company has limited financial resources and minimal operating cash flow, with no assurance of additional funding for business development. Future sales or issuances of equity securities could dilute existing investors' voting power and reduce earnings per share.

Why It Matters

Crucial Innovations' pivot to the highly regulated and competitive European medical cannabis market presents a high-risk, high-reward scenario for investors. The company's lack of significant operations and commercial sales, coupled with limited financial resources, suggests a challenging path to profitability. For employees, the uncertainty around funding and market acceptance could impact job security. Customers in the nascent European medical cannabis market might see CINV as a new entrant, but its ability to compete against larger, more established players, including pharmaceutical and wellness companies, is unproven. The broader market will watch to see if CINV can overcome significant barriers to entry and regulatory hurdles in a dynamic industry.

Risk Assessment

Risk Level: high — Crucial Innovations is an early-stage company with a limited operating history in the medical cannabis market, explicitly stating it has 'limited financial resources and minimal operating cash flow.' The company's shares are 'currently not traded on any exchange or quotation medium,' and there is no guarantee OTC Markets will accept its re-application. Furthermore, the company faces 'high barriers to entry due to licensing requirements' in the competitive European medical cannabis market, indicating significant operational and financial challenges.

Analyst Insight

Investors should exercise extreme caution and avoid Crucial Innovations' stock until the company demonstrates significant commercial sales, secures substantial funding, and successfully re-lists its shares on a trading platform. The current lack of operational history and financial stability makes it a highly speculative investment.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

N/A

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

N/A

cash Position

$0

revenue Growth

N/A

Key Numbers

• 381,320,798 — common stock shares outstanding (as of December 31, 2024)
• 418,694,150 — common stock shares outstanding (as of August 14, 2025, indicating dilution)
• 2018 — year of formation (Crucial Innovations Corp. was formed)
• 2023 — year of business change (Crucial Innovations pivoted to medical cannabis)
• $0.001 — par value per share (common stock par value)

Key Players & Entities

• Crucial Innovations Corp. (company) — registrant
• Nevada (regulator) — state of incorporation
• SEC (regulator) — Securities and Exchange Commission
• OTC Markets (company) — previous trading platform
• Colonial Stock Transfer Company (company) — transfer agent
• Sarbanes-Oxley Act of 2002 (regulator) — governing legislation
• Private Securities Litigation Reform Act of 1995 (regulator) — governing legislation
• United Kingdom (regulator) — primary market for medical cannabis
• Europe (regulator) — primary market for medical cannabis
• Board (company) — board of directors

FAQ

Risk Factors

• Intense Competition in European Medical Cannabis Market [high — market]: The European medical cannabis market is highly competitive, with significant barriers to entry due to licensing requirements. CINV faces direct competition from established cannabis producers and retailers, as well as broader competition from manufacturers in the pharmaceuticals, alcohol, tobacco, health and beauty, and functional wellness industries. Increased competition from larger, better-financed entities could materially impact the company's business and financial condition.
• Limited Financial Resources and Funding Uncertainty [high — financial]: Crucial Innovations Corp. has limited financial resources and minimal operating cash flow. There is no assurance of additional funding for business development, which is critical for its pivot into the medical cannabis sector. This lack of capital poses a significant risk to the company's ability to execute its business plan and achieve commercial sales.
• Potential for Shareholder Dilution [medium — financial]: The company has experienced significant increases in outstanding shares, from 381,320,798 as of December 31, 2024, to 418,694,150 by August 14, 2025. Future sales or issuances of equity securities could further dilute existing investors' voting power and reduce earnings per share, negatively impacting shareholder value.
• Uncertainty of Resuming OTC Trading [medium — regulatory]: CINV's shares are currently not traded on any exchange. While the company intends to re-apply to OTC Markets to resume trading after filing this 10-K, there is no guarantee that the application will be accepted or that the company will meet the listing standards. This uncertainty impacts liquidity for investors.
• Lack of Significant Operations and Commercial Sales [high — operational]: Despite pivoting to the medical cannabis business in 2023, CINV has not yet achieved significant operations or commercial sales. The company's ability to generate revenue and establish a market presence in this nascent and competitive industry remains unproven.

Industry Context

The European medical cannabis market is characterized by high competitiveness and significant regulatory barriers to entry, primarily related to licensing. Crucial Innovations Corp. faces established cannabis producers and distributors, as well as indirect competition from broader consumer product manufacturers in sectors like pharmaceuticals and wellness. The industry is still in its early stages, suggesting potential for growth but also intense competition from new entrants as demand increases.

Regulatory Implications

Navigating the complex and varied licensing requirements across different European countries presents a significant hurdle for CINV. Failure to obtain or maintain necessary licenses could halt operations. Furthermore, the company's ability to resume trading on the OTC Markets is subject to regulatory approval, impacting investor access and liquidity.

What Investors Should Do

1. Monitor CINV's progress in obtaining necessary licenses for medical cannabis operations in Europe, as this is critical for revenue generation.
2. Closely track any updates regarding the company's application to resume trading on OTC Markets, as this will affect share liquidity.
3. Assess the company's ability to secure additional funding, given its limited financial resources and minimal operating cash flow, to support its business development.
4. Be aware of the high potential for dilution due to past and potential future share issuances, which could negatively impact ownership percentage and EPS.

Key Dates

• 2018-02-28: Company Formation — Crucial Innovations Corp. was incorporated in Nevada, initially focusing on English language tutoring.
• 2023-12-31: Business Pivot to Medical Cannabis — The company shifted its business strategy from English language tutoring to becoming a supplier and distributor of medical cannabis in Europe.
• 2024-12-31: Year-End Outstanding Shares — Reported 381,320,798 shares of common stock outstanding.
• 2025-08-14: Subsequent Outstanding Shares — Outstanding shares increased to 418,694,150, indicating potential dilution for existing shareholders.

Glossary

Form 10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC) that gives a comprehensive summary of a company's financial performance. (This document provides the detailed financial and operational information for Crucial Innovations Corp. for the fiscal year ended December 31, 2024.)

OTC Markets

A trading platform for broker-dealer quotes of securities that are not listed on major exchanges like the NYSE or Nasdaq. (CINV's shares previously traded here and the company intends to re-apply, impacting potential investor liquidity and access.)

Dilution

The reduction in the ownership percentage of a shareholder resulting from the issuance of new shares. (Significant increases in outstanding shares indicate potential dilution for current investors, reducing their proportional ownership and earnings per share.)

Medical Cannabis

Cannabis used for medical purposes, often prescribed by physicians to treat specific conditions. (This is the new core business focus for Crucial Innovations Corp. after its strategic pivot.)

Year-Over-Year Comparison

This 10-K represents a significant shift from the prior year's filing, detailing a pivot from English language tutoring to the medical cannabis sector in Europe. As such, direct year-over-year comparisons of revenue, margins, and profitability are not applicable, as the company has not yet achieved significant commercial sales in its new venture. New risk factors related to market competition, regulatory hurdles in the cannabis industry, and funding uncertainties are now prominent, replacing risks associated with the previous business model.

Key Financial Figures

• $0.001 — of the registrant’s common stock, $0.001 par value, outstanding as of December 3

Filing Documents

• f10k_cinv12312024.htm (10-K) — 642KB
• ex311_ceo302certification.htm (EX-31.1) — 8KB
• ex312_cfo302certification.htm (EX-31.2) — 8KB
• ex321_ceo906certification.htm (EX-32.1) — 4KB
• ex322_cfo906certification.htm (EX-32.2) — 4KB
• image_001.jpg (GRAPHIC) — 11KB
• image_003.jpg (GRAPHIC) — 44KB
• 0001712543-25-000056.txt ( ) — 743KB

Business

Business 4 Item 1A

Risk Factors

Risk Factors 6 Item 1B Unresolved Staff Comments 10 Item 1C Cybersecurity 10 Item 2

Properties

Properties 11 Item 3

Legal Proceedings

Legal Proceedings 11 Item 4 Mine Safety Disclosures 11 PART II Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 11 Item 6 [Reserved] 11 Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 12 Item 7A Quantitative and Qualitative Information About Market Risk 15 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 16 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 35 Item 9A

Controls and Procedures

Controls and Procedures 35 Item 9B Other Information 36 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 36 PART III Item 10 Directors, Executive Officers and Corporate Governance 37 Item 11

Executive Compensation

Executive Compensation 40 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 41 Item 13 Certain Relationships and Related Transactions, and Director Independence 42 Item 14 Principal Accountant Fees and Services 42 PART IV Item 15 Exhibits and Financial Statement Schedules 43 Item 16 Form 10-K Summary 44 2 Table of Contents EXPLANATORY NOTE The following Annual Report on Form 10-K (“10-K”) for Crucial Innovations Corp. (“CINV” or the “Company”) for the year ended December 31, 2024 presents the Company and its results of operations for the periods indicated therein. Except as specifically designated herein, this 10-K does not reflect events occurring after December 31, 2024 and the Company has not otherwise updated disclosures contained herein to reflect events that occurred at a later date. 3 Table of Contents PART I

Business

Item 1. Business The Company Crucial Innovations Corp. (collectively with our subsidiary, “we,” “us,” “our,” “CINV” or the “Company”), a Nevada corporation, was formed on February 28, 2018. We were initially engaged in the business of English language tutoring over the Internet. However, we were not able to execute our original business plan, develop significant operations or achieve commercial sales. During 2023, we determined to change our business to become a supplier and distributor of medical cannabis in Europe. Our principal office is located at 86-90 Paul Street, London EC2A 4NE United Kingdom, and our telephone number is +44 (0) 203 148 1452. Our corporate website is located at www.cinvcorp.com , although it does not constitute a part of this Annual Report. We make available free of charge on our website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed or furnished to the Securities and Exchange Commission (“SEC”). Our shares have previously traded on the OTC Markets expert trading platform under the symbol ‘CINV’. Following the filing of this annual report on Form 10-K and other reports as required by the SEC, we intend to re-apply to OTC Markets to resume trading in our shares, although we may be assigned a different trading symbol at such time. Competition The medicinal cannabis market in Europe is highly competitive. Some of those markets where we will seek to operate have relatively high barriers to entry due to licensing requirements. We expect to compete directly with other cannabis producers and retailers, some of which operate only in a specific market and some of which operate across several European markets. More broadly, CINV views manufacturers of other consumer products, such as those in the pharmace

Risk Factors

Item 1A. Risk Factors An investment in our securities involves certain risks relating to our structure and investment objectives. The risks and uncertainties described below are not the only ones facing the Company. You should carefully consider these risks, together with all of the other information included in this 10-K, including our financial statements and the related notes thereto. Additional risks and uncertainties not presently known to us, or not presently deemed material by us, may also impair our operations and performance. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected. If that happens, the trading price of our common stock could decline and you may lose all or part of your investment. Risks Related to Our Common Stock Our shares are currently not traded on any exchange or quotation medium . Previously, our shares were traded on the OTC Markets trading platform. Following the filing of this annual report on Form 10-K and other reports as required by the SEC, we intend to re-apply to OTC Markets to resume trading in our shares. We cannot guarantee that OTC Markets will accept our application or that we will otherwise qualify under the listing standards of OTC Markets. If our shares are able to resume trading, we could experience higher trading volumes and volatility in the future. This volatility may affect the price at which you could sell our common stock and the sale of substantial amounts of our common stock could adversely affect the price of our common stock . If our stock resumes trading on OTC Markets or other trading platform, it could experience significant price swings. This volatility may affect the price at which you could sell our common stock, and the sale of substantial amounts of our common stock could adversely affect the price of our common stock. Our share price is expected to be volatile and subject to significant price and volume

View Full Filing

View this 10-K filing on SEC EDGAR